The liver X receptor (LXR) is a nuclear hormone receptor that is one of the most important regulators of cholesterol homeostasis and plays a key role in triglyceride (TG) regulation. Researchers from Orsobio Inc. and Phenex Pharmaceuticals AG have presented preclinical data on TLC-2716, a potent, small-molecule LXR inverse agonist for the treatment of lipid disorders.